Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses the authors' concerns over the misinterpretation of studies linking smoking and frontal fibrosing alopecia, clarifying that neither study suggests smoking is protective against the condition.

In this study of female pattern hair loss, oral finasteride 5 mg and topical minoxidil 5% both significantly improved hair density and patient satisfaction over 6 months, outperforming finasteride 2 mg, which showed limited improvement beyond the third month. All treatments were deemed safe.

This study found that oral tofacitinib at a 5mg twice daily dosage was effective in treating recalcitrant alopecia areata, showing significant improvement in hair regrowth and a 27% reduction in SALT scores over six months, with minimal side effects among the 19 patients monitored.

This study found that early intervention and treatment with intralesional triamcinolone acetonide may stabilize hairline recession in patients with frontal fibrosing alopecia, although further research is needed for definitive treatment guidelines.

This narrative review explores the failure of fludalanine as an orally active antibiotic and highlights valuable insights into problem-solving strategies in drug discovery, without reporting new clinical results.

This review discusses frontal fibrosing alopecia and reports no clinical results; the authors note that no therapeutic options tested, including corticosteroids, finasteride, and minoxidil, have shown clear benefits.

In this observational study, most patients with multiple sclerosis on teriflunomide who experienced hair thinning reported it as mild or moderate and largely recovered while continuing treatment.

This review reports no new results and discusses various topical treatments, noting that fluocortin butyl ester offers anti-inflammatory effects without systemic side effects, while combinations outperform single-agent therapies in managing hyperpigmentation.

Linalool in fragrances may harm hair follicles and contribute to hair loss.

This review highlights current treatment options for frontal fibrosing alopecia, noting that 5-α-reductase inhibitors, intralesional steroids, and hydroxychloroquine have the highest evidence of effectiveness, while other therapies show variable results and need further research.

This article reviews the prescription-only cream eflornithine for managing facial hirsutism in women and reports no new clinical results; the authors evaluate its potential role in treatment.

Finasteride is a medicine used to treat enlarged prostate and prostate cancer, and it works by changing how testosterone works in the body.

Finasteride and dutasteride can improve hair loss in women, but more research is needed.

This study observed that antisense oligonucleotides targeting FGFR-1 increased cellular activity in hair follicle cultures from mice, suggesting potential clinical utility for treating baldness.

This study found that a low dose of flutamide, both alone and combined with an oral contraceptive, effectively reduced hirsutism in women, with the combination showing more lasting effects post-treatment.

This case report discusses the use of a prostaglandin analogue for treating eyebrow loss in a patient with frontal fibrosing alopecia, but provides no new clinical results.

In this study, clobetasol propionate foam demonstrated effectiveness and good patient compliance as a safe topical treatment for moderate to severe alopecia areata, with significant hair regrowth compared to placebo.

This article discusses the formulation and evaluation of hair gels that may improve the treatment and prevention of dandruff by providing longer-lasting effects compared to traditional shampoos and lotions, but it reports no new clinical findings.

This study found that a cream containing 2% Fennel extract reduced hair diameter in idiopathic hirsutism patients more effectively than a cream with 1% Fennel or a placebo.

This review discusses the preclinical and clinical data on teriflunomide for multiple sclerosis, highlighting its selective action on immune cells without causing clinical immune suppression, and provides no new clinical results.

Recent Phase III trials reported that once daily 5% minoxidil foam significantly increased hair count in women with female pattern hair loss and was shown to be as effective as twice daily 2% minoxidil solution.

This clinical trial found that transdermal delivery of 5-Fluorouracil using fractional CO2 laser resulted in a significantly better treatment response in alopecia areata patients compared to intralesional injections of the same drug, with a greater reduction in the Severity of Alopecia Tool Score.

This study reports that oral tofacitinib treatment in a patient with refractory lichen planus pigmentosus and frontal fibrosing alopecia resulted in near-complete resolution of hyperpigmentation and cessation of hairline recession over 18 months, and suggests it may be a promising therapy for these challenging conditions.

This study suggests that topical finasteride may benefit women with facial hirsutism, based on observations from a small sample.

This study found that after 12 months of treatment with 5 mg of finasteride, patients with benign prostatic hyperplasia showed reduced prostate volume, DHT and PSA levels, and improved urinary flow rates and symptoms.

In this study, FCE 28260 showed greater potency than finasteride in inhibiting 5α-reductase enzymes and reducing prostate DHT levels in rats.

In this randomized controlled study, topical Flutamide 1% gel, applied twice daily for eight weeks, significantly reduced papules and pustules in patients with mild to moderate acne vulgaris compared to baseline.